4,209 Shares in Revolution Medicines, Inc. $RVMD Purchased by Cetera Investment Advisers

Cetera Investment Advisers acquired a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,209 shares of the company’s stock, valued at approximately $409,000.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in Revolution Medicines by 6.7% during the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock valued at $1,331,739,000 after buying an additional 1,056,792 shares during the period. Janus Henderson Group PLC raised its stake in shares of Revolution Medicines by 8.3% in the fourth quarter. Janus Henderson Group PLC now owns 12,303,502 shares of the company’s stock valued at $980,036,000 after acquiring an additional 947,448 shares during the period. Nextech Invest Ltd. lifted its holdings in shares of Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after acquiring an additional 1,304,347 shares during the last quarter. Paradigm Biocapital Advisors LP boosted its stake in shares of Revolution Medicines by 6.8% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 6,644,403 shares of the company’s stock worth $529,227,000 after purchasing an additional 421,112 shares during the period. Finally, Bellevue Group AG grew its holdings in Revolution Medicines by 21.7% during the 3rd quarter. Bellevue Group AG now owns 5,573,838 shares of the company’s stock valued at $260,298,000 after purchasing an additional 994,538 shares during the last quarter. 94.34% of the stock is owned by institutional investors.

Revolution Medicines Price Performance

Shares of RVMD stock opened at $211.74 on Friday. The company has a market capitalization of $45.38 billion, a P/E ratio of -24.01 and a beta of 1.39. The company’s 50-day simple moving average is $186.87 and its two-hundred day simple moving average is $144.05. Revolution Medicines, Inc. has a one year low of $35.42 and a one year high of $220.34. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the previous year, the company earned ($1.31) EPS. As a group, equities analysts anticipate that Revolution Medicines, Inc. will post -8.82 EPS for the current year.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 20,000 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total value of $3,366,600.00. Following the completion of the sale, the chief financial officer directly owned 123,269 shares in the company, valued at approximately $20,749,870.77. This represents a 13.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Margaret A. Horn sold 29,600 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $160.12, for a total value of $4,739,552.00. Following the transaction, the chief operating officer directly owned 154,647 shares in the company, valued at $24,762,077.64. The trade was a 16.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 132,497 shares of company stock worth $21,470,486 over the last quarter. Insiders own 7.60% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on RVMD shares. Royal Bank Of Canada raised their price objective on shares of Revolution Medicines from $182.00 to $203.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Truist Financial increased their price target on Revolution Medicines from $210.00 to $231.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Wolfe Research reissued an “outperform” rating and set a $220.00 price target on shares of Revolution Medicines in a research note on Monday, August 10th. Mizuho boosted their price objective on Revolution Medicines from $185.00 to $215.00 and gave the company an “outperform” rating in a report on Monday, July 6th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $195.00 price objective on shares of Revolution Medicines in a research report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Revolution Medicines currently has an average rating of “Moderate Buy” and an average price target of $166.33.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.